Pharmaceutical Care Practice Of IVF-ET Patients In A Reproductive Medicine Center Of A Hospital

Objective:To improve the clinical pregnancy rate and medication compliance of patients in Reproductive Medicine Center in our hospital,so as to optimize the treatment program and to provide evidence for clinical treatment by analyzing therapeutic schemes of the patients with in vitro fertilization/intracytoplasmic sperm injection and embryo transfer(IVF/ICSI-ET)and doing the pharmaceutical monitoring with the patients’ individual medication adjustment.Methods:The patients with IVF/ICSI-ET in the Reproductive Medicine Center of our Hospital were selected as the research object.The two groups of patients who received the antagonist program of hyperovulation and the long-acting program of follicular phase during the period from July 2018 to March 2019 were used as the control group respectively,and the patients who received the antagonist program of hyperovulation and the long-acting program of follicular phase during the period from April to December 2019 were used as the pharmaceutical care group respectively.The above female patients were 20-40 years old,and their basic endocrine level was in the normal range.The thyroid function was normal.Hematuria routine,liver and kidney function,fasting blood glucose,chest radiograph and electrocardiogram were normal.Retrospective analysis was used in the control group and pharmacist intervention was added in the pharmaceutical care group.Basic data,ovulation induction,and clinical pregnancy rate during transplantation were compared between the two groups.SPSS software was used for statistical analysis,and P<0.05 was considered statistically significant.Results:There was no difference between the two groups in general condition,infertility years and basal hormone levels.After the pharmacist’s intervention,the Gn days,the total amount of Gn,number of oocytes,endometrial thickness at HCG day,early abortion rate showed no significant difference.In COS antagonists schemes,the drug cost in the pharmaceutical group was significantly lower than the control group(P<0.05),and the clinical pregnancy rate is significantly higher than the control(P<0.05).In COS follicular stage long-acting schemes,HCG day and LH levels in the pharmaceutical group were significantly higher than the control group(P<0.05).Conclusion:The clinical pregnancy rate and rational level of clinical medication are effectively improved,and patient satisfaction is increased by the pharmaceutical care and education for the patients undergoing IVF/ICSI-ET cycle in the COS process.Therefore,pharmaceutical care plays an active role in the treatment of patients undergoing in vitro fertilization.